title: Drug-eluting stents for acute coronary syndrome: a meta-analysis of randomized controlled trials.
abstract: Drug-eluting stents (DES) are increasingly used for treatment of acute coronary syndrome (ACS). However, clinical efficacy and safety of various types of DES is not well established in these subjects. We therefore evaluated clinical utility of second-generation and first-generation DES in patients with ACS by conducting a meta-analysis.
  
  
  
  A search of Medline, Embase, the Cochrane databases, and Web of Science was made. Randomized controlled trials (RCTs) which compared second-generation DES (everolimus-eluting stents [EES] or zotarolimus-eluting stents [ZES]) versus first-generation DES (sirolimus-eluting stents [SES] or paclitaxe-eluting stents [PES]) in patients with ACS and provided data on clinical efficacy or safety endpoints were included. Pooled estimates were calculated using random-effects model.
  
  
  
  A total of 2,757 participants with ACS in 6 RCTs were included. Compared with first-generation one, second-generation DES trended to be associated with the decreased incidence of definite or probable stent thrombosis in ACS patients (risk ratio [RR]  = 0.60, 95% confidence intervals [CI] 0.33 to 1.07, p = 0.09). However, the rate of target lesion revascularization (TLR) significantly increased in second-generation DES (RR = 2.08, 95%CI 1.25 to 3.47, p = 0.005). There were no significant differences in the incidence of major adverse cardiac events (MACEs), all-cause death, cardiac death, and recurrent myocardial infarction between the two arms (all p>0.10). The second-generation EES showed a tendency towards lower risk of MACEs (p = 0.06) and a beneficial effect on reducing stent thrombosis episodes (p = 0.009), while the second-generation ZES presented an increased occurrence of MACEs (p = 0.02) and TLR (p = 0.003).
  
  
  
  Second-generation DES, especially EES, appeared to present a lower risk of stent thrombosis, whereas second-generation ZES might increase the need for repeat revascularization in ACS patients. During coronary interventional therapy, DES class should be adequately considered in order to maximize clinical benefit of DES implantation in these specific subjects.
authors.affiliation: Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, P.R. China ; FengHe (ShangHai) Information Technology Co., Ltd, Shanghai, P.R. China.
authors.forename: Lishan
authors.initials: L
authors.lastname: Wang
mesh_terms: D054058:Acute Coronary Syndrome / Q000401:mortality / Q000628:therapy*; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016896:Treatment Outcome
references.citation: Eur J Clin Invest. 2012 Oct;42(10):1047-54
references.pmid: 22624990
references.citation: Int J Cardiol. 2012 Oct 18;160(3):181-6
references.pmid: 21546100
references.citation: Am Heart J. 2013 Jan;165(1):80-6
references.pmid: 23237137
references.citation: Lancet. 2012 Oct 27;380(9852):1482-90
references.pmid: 22951305
references.citation: J Am Coll Cardiol. 2010 Oct 5;56(15):1187-95
references.pmid: 20883925
references.citation: Int J Cardiol. 2013 Sep 30;168(2):960-6
references.pmid: 23164597
references.citation: N Engl J Med. 2007 Mar 8;356(10):998-1008
references.pmid: 17296824
references.citation: Arch Intern Med. 2012 Apr 23;172(8):611-21; discussion 621-2
references.pmid: 22529227
references.citation: Am J Cardiol. 2011 Nov 1;108(9):1207-13
references.pmid: 21872193
references.citation: N Engl J Med. 2010 May 6;362(18):1663-74
references.pmid: 20445180
references.citation: J Am Coll Cardiol. 2012 Jul 31;60(5):381-7
references.pmid: 22835668
references.citation: Thrombosis. 2012;2012:126369
references.pmid: 22655192
references.citation: JAMA. 2005 May 4;293(17):2109-17
references.pmid: 15870414
references.citation: Lancet. 2010 Jan 16;375(9710):201-9
references.pmid: 20060578
references.citation: Am J Cardiol. 2010 Mar 15;105(6):813-8
references.pmid: 20211324
references.citation: BMJ. 2007 Nov 3;335(7626):914-6
references.pmid: 17974687
references.citation: EuroIntervention. 2011 Dec;7(8):936-43
references.pmid: 21959255
references.citation: J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91
references.pmid: 17174201
references.citation: JACC Cardiovasc Interv. 2009 Jun;2(6):515-23
references.pmid: 19539255
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: N Engl J Med. 2009 May 7;360(19):1946-59
references.pmid: 19420364
references.citation: Lancet. 2012 Apr 14;379(9824):1393-402
references.pmid: 22445239
references.citation: Cochrane Database Syst Rev. 2010 May 12;(5):CD004587
references.pmid: 20464732
references.citation: J Am Coll Cardiol. 2006 Dec 19;48(12):2440-7
references.pmid: 17174180
references.citation: Circ J. 2009 Dec;73(12):2229-35
references.pmid: 19789418
references.citation: Am J Cardiol. 2009 Nov 15;104(10):1370-6
references.pmid: 19892052
references.citation: Chin Med J (Engl). 2012 Oct;125(19):3373-81
references.pmid: 23044291